Psilocybin for depression: all studies (page 36)

Systematic Review on the Mechanisms of Action of Psilocybin in the Treatment of Depression

European Psychiatry March 1, 2023 M. C. Q. Lin, H. Lee, V.-W.-L. Tsang et al.

Introduction Despite emerging evidence suggesting the efficacy of psilocybin in the treatment of mood disorders such as depression, the exact mechanisms by which psilocybin is able to elicit these antidepressant effects remains unknown. Objectives As the use of psilocybin as a treatment modality for depression has garnered increasing interest, this study aims to summarize the existing evidence...

DOI: 10.1192/j.eurpsy.2023.898

Psychedelics for depression: from neurobiology to treatment

European Psychiatry March 1, 2023 K. P. Kuypers 2 citations

Abstract Decades ago, the classical psychedelics psilocybin and LSD entered the therapeutic setting and already then showed their therapeutic potential in the treatment of psychiatric disorders. For thousands of years another psychedelic, ayahuasca, is being used by tribes in western Amazonia for healing and divination, and in recent years its use has expanded worldwide. Research into the...

DOI: 10.1192/j.eurpsy.2023.74 Full text Psilocybin Psychotherapist Therapeutic effect Therapeutic approach +3

The therapeutic potential of psilocybin in depression resistant to psychotropic drugs

European Psychiatry March 1, 2023 J. Ramírez González, I. Fernández Márquez, Serafín González et al.

Introduction The use of hallucinogens has accompanied the human being throughout history. In the 1970s, studies focused on the therapeutic potential of hallucinogens were blocked due to their misuse in the young population. At present, psilocybin is re-emerging as the center of attention due to its possible therapeutic potential in different psychiatric pathologies such as depression, anxiety...

DOI: 10.1192/j.eurpsy.2023.1767 Full text Psilocybin Anxiety Major depressive disorder Hallucinogen +4

Improvement in Depression Symptoms Measured by Montgomery-Åsberg Depression Rating Scale and Quick Inventory of Depressive Symptomatology-Self Rated Items after Randomised Double-blind COMP360 Psilocybin Therapy for Treatment-resistant Depression

European Psychiatry March 1, 2023 Guy M. Goodwin, Lindsey Marwood, Sunil Mistry et al. 1 citation

Introduction COMP360 is a synthetic, proprietary, purified form of psilocybin in development for treatment-resistant depression (TRD) with FDA Breakthrough Therapy designation. In a recent phase IIb study, COMP360 psilocybin 25mg was superior to 1mg on change from baseline (CFB) to Week 3 on the Montgomery-Åsberg Depression Rating Scale (MADRS) total score (primary efficacy endpoint), when...

DOI: 10.1192/j.eurpsy.2023.273 Full text Psilocybin Depression economics Rating scale Sadness +5

A Single Administration of Psilocybin Persistently Rescues Cognitive Deficits Caused by Adolescent Chronic Restraint Stress Without Long-Term Changes in Synaptic Protein Gene Expression in a Rat Experimental System with Translational Relevance to Depression.

Psychedelic Medicine March 1, 2023 Meghan Hibicke, Hannah M. Kramer, Charles D. Nichols 25 citations

Psilocybin has shown long-lasting antidepressant effects in preclinical and clinical trials, but the mechanisms responsible are unclear. As both passive coping strategies and pattern separation deficits are characteristics of major depression, we used adult female rats subjected to adolescent chronic restraint stress (aCRS) to investigate the effects of psilocybin on forced swim test (FST) and...

DOI: 10.1089/psymed.2022.0012 Full text Depression Psilocybin Adolescent stress Pattern separation +8

Serotonergic psychedelics for depression: What do we know about neurobiological mechanisms of action?

Frontiers in Psychiatry February 10, 2023 Muhammad Ishrat Husain, Nicole Ledwos, Elise Fellows et al. 47 citations

Introduction Current treatment options for major depressive disorder (MDD) have limited efficacy and are associated with adverse effects. Recent studies investigating the antidepressant effect of serotonergic psychedelics—also known as classic psychedelics—have promising preliminary results with large effect sizes. In this context, we conducted a review of the putative neurobiological...

DOI: 10.3389/fpsyt.2022.1076459 LSD Ayahuasca Psilocybin Psychedelics hallucinogens +6

Single-dose psilocybin for a treatment-resistant episode of major depression: Impact on patient-reported depression severity, anxiety, function, and quality of life

Journal of Affective Disorders February 3, 2023 Guy M. Goodwin, Scott T Aaronson, Oscar Alvarez et al. 168 citations

Three weeks after dosing, psilocybin 25 mg and, to a lesser degree, 10 mg improved measures of patient-reported depression severity, anxiety, affect, and functioning. These results extend the primary findings from the largest randomised clinical trial of psilocybin for TRD to examine other outcomes that are of importance to patients.

DOI: 10.1016/j.jad.2023.01.108 Anxiety Psilocybin Antidepressant Patient-reported outcomes +5

Psychedelic therapy for depressive symptoms: A systematic review and meta-analysis.

Journal of Affective Disorders February 1, 2023 Kwonmok Ko, Emma I Kopra, Anthony J. Cleare et al. 144 citations

Psychedelic therapy shows promise for Major Depressive Disorder, especially when treatment-resistant, as well as life-threatening illness distress. The objective of this systematic review, inclusive of meta-analysis, is to examine recent clinical research on the therapeutic effects of classic psychedelics on depressive symptoms. Fourteen psychedelic therapy studies, utilising psilocybin,...

DOI: 10.1016/j.jad.2022.09.168 Full text Ayahuasca Depression LSD Psilocybin +7

5-HT2ARs Mediate Therapeutic Behavioral Effects of Psychedelic Tryptamines.

ACS Chemical Neuroscience February 1, 2023 Lindsay P. Cameron, Seona D Patel, Maxemiliano V. Vargas et al. 113 citations

Psychedelic compounds have displayed antidepressant potential in both humans and rodents. Despite their promise, psychedelics can induce undesired effects that pose safety concerns and limit their clinical scalability. The rational development of optimized psychedelic-related medicines will require a full mechanistic understanding of how these molecules produce therapeutic effects. While the...

DOI: 10.1021/acschemneuro.2c00718 Full text 5-ht2a receptor Depression Neuroplasticity Psilocybin +12

Single-dose psilocybin-assisted therapy in major depressive disorder: A placebo-controlled, double-blind, randomised clinical trial.

EClinicalMedicine February 1, 2023 Robin von Rotz, Eva M Schindowski, Johannes Jungwirth et al. 345 citations

Psilocybin has been suggested as a novel, rapid-acting treatment for depression. Two consecutive doses have been shown to markedly decrease symptom severity in an open-label setting or when compared to a waiting list group. To date, to our knowledge, no other trial compared a single, moderate dose of psilocybin to a placebo condition. In this double-blind, randomised clinical trial, 52...

DOI: 10.1016/j.eclinm.2022.101809 Full text Depression Major depressive disorder Psychedelic-assisted therapy Magic mushrooms +8